CN101007801A - Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses - Google Patents
Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses Download PDFInfo
- Publication number
- CN101007801A CN101007801A CNA2006100650024A CN200610065002A CN101007801A CN 101007801 A CN101007801 A CN 101007801A CN A2006100650024 A CNA2006100650024 A CN A2006100650024A CN 200610065002 A CN200610065002 A CN 200610065002A CN 101007801 A CN101007801 A CN 101007801A
- Authority
- CN
- China
- Prior art keywords
- methyl
- trifluoromethyl
- pyrroles
- hydrogen
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 title description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 229960005181 morphine Drugs 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- -1 amine acyl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 150000003233 pyrroles Chemical class 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 9
- 108091000080 Phosphotransferase Proteins 0.000 claims description 8
- 102000020233 phosphotransferase Human genes 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 7
- 102000001253 Protein Kinase Human genes 0.000 abstract description 6
- 108060006633 protein kinase Proteins 0.000 abstract description 6
- 230000004064 dysfunction Effects 0.000 abstract description 3
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000009423 ventilation Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 55
- 239000002994 raw material Substances 0.000 description 39
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 108091008605 VEGF receptors Proteins 0.000 description 27
- 238000001819 mass spectrum Methods 0.000 description 25
- 238000003756 stirring Methods 0.000 description 20
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 19
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 8
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 6
- 108091008606 PDGF receptors Proteins 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- RNJDYPPMAYIKOM-UHFFFAOYSA-N C(C)(C)(C)OC(CC(C)=C=O)=O Chemical compound C(C)(C)(C)OC(CC(C)=C=O)=O RNJDYPPMAYIKOM-UHFFFAOYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- HERWQQFSESWGRK-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridin-1-ium chloride Chemical compound Cl.N1=CC=CC=C1.[O-2].[O-2].[O-2].[Cr+6] HERWQQFSESWGRK-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- FGFUBBNNYLNVLJ-UHFFFAOYSA-N indolone Natural products C1=CC=C2C(=O)C=NC2=C1 FGFUBBNNYLNVLJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WIHIUTUAHOZVLE-UHFFFAOYSA-N 1,3-diethoxypropan-2-ol Chemical compound CCOCC(O)COCC WIHIUTUAHOZVLE-UHFFFAOYSA-N 0.000 description 1
- ASFAFOSQXBRFMV-LJQANCHMSA-N 3-n-(2-benzyl-1,3-dihydroxypropan-2-yl)-1-n-[(1r)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]benzene-1,3-dicarboxamide Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(=O)C(C=1)=CC(N(C)S(C)(=O)=O)=CC=1C(=O)NC(CO)(CO)CC1=CC=CC=C1 ASFAFOSQXBRFMV-LJQANCHMSA-N 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101000953655 Danio rerio Vascular endothelial growth factor receptor kdr-like Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to 2- dihydroindole-ones derivatives or its salt demonstrated in general formula (I), and the substituent group in formula is demonstrated in instruction manual. The invention also relates to the compound comprising said derivatives, method for preparing the same, and the application for preventing and treating cell dysfunction of pulmonary ventilation relevant to protein kinase.
Description
Technical field
The present invention relates to the 2-indolinone derivative that a kind of pyrroles replaces, 3-(3-trifluoromethyl-4-amidopyrrol-2-methylene)-2-indolinone derivative particularly, its preparation method and this derivative purposes in the preparation kinases inhibitor.
Background technology
(Protein kinases PKs) has important effect to protein kinase in the signal conductive process.It can be transferred to γ-phosphate of ATP on the particular amino acid residue of functional protein, causes a series of biological respinses.According in the phosphorylation process as the amino acid classification of substrate, protein kinase can be divided into serine-threonine kinase (STKs) and Tyrosylprotein kinase (PTKs).
Nearly 100 kinds of protein tyrosine kinases (protein tyrosine kinases) have been determined aminoacid sequence (Hanks and Hunter, 1995, FASEB J.9:576-596), and appreciable amt may reach 1000 kinds.
Tyrosine phosphorylation mechanism is prevalent in the signal conductive process, regulating and control such as various kinds of cell functions such as mitotic division, cell cycle progression and differentiation (Hanks and Hunter, 1995, FASEB is J.9:576-596; Cadena and Gill, 1992, FASEB is J.6:2332-2337; Schlessinger and Ullrich, 1992, Neuron9:383-391; Vandergeer et al., 1994, Annu.Rev.Cell Biol.10:251-337).When protein tyrosine kinase is expressed under variation, situation out of control, or when under abnormal high level, expressing, normal cell can be changed into tumour phenotype (neoplastic phenotype) (Chiao et al., 1994, Cancer Metast.Rev.9:63-80; Hunter, 1991, Cell 64:249-270).
The most cells growth factor receptors contains the peptide chain-ordering of Tyrosylprotein kinase, the overexpression of visible different tyrosine kinase receptors or excessive activation in many tumours, as the overexpression of common EGFR family in the epithelial cell tumour, the overexpression of the growth factor receptors (PDGFR) in common thrombocyte source etc. in the glioma.Similarity and some other structural characteristics according to the peptide chain-ordering, these acceptors are divided into some families: be the receptor family of representative with EGF-R ELISA (EGFR) 1), comprise EGFR, HER2, HER3 and HER4 etc., the high expression level of this receptoroid is common in the epithelial cell tumour; 2) Insulin Receptor Family comprises insulin receptor, IGF-1 (IGF-R) and Regular Insulin associated receptor (IRR) etc., the high expression level of common this receptoroid in leukemia; 3) platelet-derived growth factor receptors (PDGFR) family comprises PDGFR
α, PDGFR
β, clone's stimulating factor (CSF-1R), c-Kit etc., this receptoroid is common high expression level in cerebral tumor and leukemia; 4) bfgf receptor (FGFR) includes FGFR1, FGFR2, and FGFR3, FGFR4 and keratinocyte growth factor acceptor etc., this receptoroid plays an important role aspect vasculogenesis; 5) vascular endothelial growth factor receptor (VEGFR) is the important positivity regulatory factor of vasculogenesis; In addition, also have hepatocyte growth factor receptor (HGFR) class, Fibronectin III receptor class and the tame same clan of nerve growth factor acceptor (NGFR).Tyrosine kinase receptor overexpression in different types of tumors respectively causes the interior abnormal signal of its cell to activate, and causes cell transformation, constantly breeds, and promotes generation, the development of tumour, resists apoptosis, upsets the growth balance of cell.Therefore, target tyrosine kinase signal approach is good antitumor strategy.
Vascular endothelial growth factor (vascular endothelial growth factor, VEGF) be the somatomedin of main vasoactive endotheliocyte, have the endothelial cell proliferation of promotion, increase multiple function (Hanks and Hunter such as microvascular permeability, induction of vascular generation, 1995, FASEB J.9:576-596).VEGF be at present known to the most effective, direct acting angiopoietin-like 4 protein (angiogenic protein), be a kind of diffusible endothelial cell specific mitogen and angiogenesis factor (Ferrara N et al., EndocrRev.1997,18,4-25; Tofimura T et al., Hum Pharthol.1998,29,986-991).VEGF family comprises that 6 member: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta generate the factor (PDF) at present, be dimer glycoprotein form, and the sterie configuration that all contains 8 regular cystine residues, the tool specificity is considered to " cystine knot " (cysteine knot).Li Ling etc. (Li Ling etc. Acta Biochimica et Biophysica Sinica, 2002,34 (1), 21-27) find malignant cell high level expression VEGF, and find also high level expression Flk-1 of tumour cell, the prompting tumor by local exists VEGF autocrine and paracrine path.The expression of VEGF and the microvessel density of some solid tumors have dependency, and the concentration of VEGF is relevant with the prognosis of some solid tumor in the tissue, as mammary cancer, lung cancer, prostate cancer and colorectal carcinoma.Known anoxic is the important factor that stimulates VEGF to produce, and the not raising of only genetic transcription rate of hypoxia inducible VEGF genetic expression in tumour cell also has the enhancing of VEGF mRNA stability.Clearly there are 3 kinds of VEGFR-1/Fit-1, VEGFR-2/Flk-1/KDR and VEGFR-4/FIt-4 in VEGFR family, and VEGFR-1 and VEGFR-2 are the cell surface tyrosine kinase receptor, mainly are positioned at the tumor vascular endothelial cell surface.Vascular endothelial growth factor (vascular endothelial growth factor, VEGF) and vascular endothelial growth factor receptor (vascularendothe-lial growth factor receptor, VEGFR) in the tumor neogenetic blood vessels forming process, play an important role, and become the important target spot that anti-tumor biological is treated.
Be that the oncotherapy of target spot mainly contains following five kinds with VEGF and VEGFR at present: 1. (EllisLM et al.J Biol Chem 1998,273,1052-1057): VEGF and VEGFR play positive control for neonate tumour blood vessel in gene therapy.By gene therapy, make VEGF and VEGFR expression decreased, or block its signal transduction pathway, thereby suppress the two performance biologic activity.2。Anti-VEGF/VEGFR monoclonal antibody (Gordon Met al.Proc Am Soc Clin Oneol, I998, I7,2IIa): the monoclonal antibody of using VEGF and VEGFR, can seal excretory VEGF and VEGFR, the endothelium signal transduction that stops VEGF to bring out suppresses the formation of blood vessel.3 small molecules inhibitions: by the su series compound of sugen company development.4。Soluble VEGFR: solvable VEGFR only has the binding ability with VEGF, but no signal transduction function.5。Two principal recipient Fit-1 of targeted therapy: VEGF and Flk-1/KDR overexpression in tumor vascular endothelial cell, and VEGFR almost can not detect in adjacent healthy tissues blood vessel endothelium.Therefore, VEGF and VEGFR provide specificity higher target spot for the targeted therapy of tumour, VEGF can with couplings such as other antitumor drugs, toxin, radionuclide, be used for the targeted therapy of tumour.
In the prior art, for example at WO9850356, WO0202551, WO02055517, WO0164681 discloses indole ketone compound among WO0160814 and the WO02096361 etc., and has announced that they are of value to the propagation of controlling improper cell by the inhibition Tyrosylprotein kinase.The su series compound of sugen company exploitation particularly, can be used as KDR/FIk-1, pdgf receptor and FGF acceptor is the inhibitor of RTK widely of target spot, plays a role by a plurality of target spots.
Summary of the invention
One object of the present invention is to provide a kind of 2-indolinone derivative, particularly 3-(3-trifluoromethyl-4-amidopyrrol-2-methylene)-2-indolinone derivative of pyrroles's replacement.
Therefore, the present invention relates to the 2-indolinone derivative that the pyrroles shown in the general formula (I) replaces, and their tautomer, enantiomorph, diastereomer, raceme and physiologically acceptable salt, wherein said tautomer comprises Z configuration and E configuration.
Wherein:
R
1, R
2, R
3And R
4Be selected from respectively hydrogen atom, halogen, alkyl, haloalkyl, halogenated alkoxy, cycloalkyl, thiazolinyl, alkynyl, aryl, heteroaryl, Heterocyclylalkyl, hydroxyl ,-OR
8,-O[CH
2CH
2O]
rR
11,-SR
8,-NR
10R
11,-SOR
8,-SO
2R
8,-NSO
2R
8,-SO
2NR
8R
9,-(CH
2)
nCOOR
8,-(CH
2)
nCONR
8R
9,-C (=S) NR
8R
9,-COR
8,-NR
8COR
9,-NHC (=O) OR
9,-OCOOR
9,-OCONR
8R
9,-CN or-NO
2, wherein aryl, heteroaryl, Heterocyclylalkyl functional group can further be replaced by alkyl or halogen;
R
5And R
6Have at least one to be trifluoromethyl; R
5And R
6Be selected from hydrogen atom, alkyl, aryl or trifluoromethyl respectively;
R
7Be selected from hydrogen atom, alkyl or-(CO) R
10
R
8And R
9Be selected from hydrogen atom, alkyl, cycloalkyl, aryl, heteroaryl or Heterocyclylalkyl respectively, wherein alkyl, cycloalkyl, aryl, heteroaryl or Heterocyclylalkyl can further be replaced by one or more alkyl, aryl, hydroxyl, amino, alkylamino, amide group, amine acyl group, cyano group, alkoxyl group, aryloxy, amine alkyl, hydroxyalkyl, Heterocyclylalkyl, carboxylic acid or carboxylicesters;
Simultaneously, R
8And R
9Can form 4～8 yuan of heterocyclic radicals; Wherein can further contain one or more N, O, S atom in 5～8 yuan of heterocycles, and can be further on 4～8 yuan of heterocycles by one or more alkyl, aryl, heteroaryl, haloalkyl, halogenated alkoxy, hydroxyl, amino, alkylamino, amide group, amine acyl group, cyano group, alkoxyl group, aryloxy, amine alkyl, hydroxyalkyl, Heterocyclylalkyl, carboxylic acid, carboxylicesters, halogen or-NR
8R
9Replace;
R
10Be selected from hydroxyl, alkoxyl group, aryloxy, heterocycle alkoxyl group, aralkoxy ,-N (R
11) (CH
2)
mR
12,-NR
11[CH
2CH
2O]
rR
11,-NR
8R
9Perhaps-NR
11(CH
2)
m[CH (OH) CH
2]
pZ, wherein Z be aryl, heteroaryl, Heterocyclylalkyl ,-NR
8R
9,-COOR
11Or CONR
8R
9
R
11Be selected from hydrogen atom or alkyl;
R
12Be selected from-NR
8R
9, hydroxyl, aryl, heteroaryl, alkoxyl group ,-O[CH
2CH
2O]
rR
11,-N
+(O
-) R
8R
9,-N (OH) R
8,-NHC (O) R
13Or-COR
13, R wherein
13Be unsubstituted alkyl, haloalkyl or aralkyl;
N is 0～4;
R is 1～6;
M is 1～6;
P is 1～2.
In the described compound or its salt of general formula of the present invention (I), R preferably
5It is trifluoromethyl;
Typical compound of the present invention includes, but are not limited to:
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-Toluidrin-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(6-ethanamide-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-Toluidrin-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(6-amino-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide;
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide;
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide;
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide; With
5-(6-amino-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide.
Another object of the present invention is to provide a kind of pharmaceutical composition, it comprises 2-indolinone derivative or its salt and the pharmaceutically acceptable carrier as the described pyrroles's replacement of general formula of the present invention (I) of medicine effective dose.
Another object of the present invention is to provide the preparation method of the 2-indolinone derivative that a kind of pyrroles replaces, may further comprise the steps:
Trifluoromethyl compound a cyclization is generated trifluoromethyl compound c;
Described trifluoromethyl compound c is become compound d by the mineral alkali selective hydrolysis;
Trifluoromethyl compound e is oxidized to compound f by PCC.
The purposes of the 2-indolinone derivative compound or its salt that the pyrroles that a further object of the present invention is to provide shown in the present replaces in the preparation kinases inhibitor.Derivative of the present invention can be regulated the activity of protein kinase, therefore can be used for the prevention and the treatment of protein kinase dependency cell dysfunction.Thereby as seen, compound of the present invention can also be used for the treatment of and relate to the active dysfunction of unusual PK.
The synthetic method of The compounds of this invention
In order to finish purpose of the present invention, the present invention adopts following technical scheme:
In order to prepare compound of the present invention, mainly finish with following general synthetic method:
Raw material a is obtained compound b with the Sodium Nitrite reaction in the presence of acetic acid; The cyclization under the zinc powder effect of compound b and 3-carbonyl-butyric acid-tert-butyl ester obtains compound c; Make solvent with tetrahydrofuran (THF), first alcohol and water, the ester hydrolysis takes place and obtains compound d in compound c under the potassium hydroxide effect; Compound d obtains Verbindung through borane reduction; Verbindung is oxidized to aldehyde cpd f through PCC; Further, compound f obtains compound g after sloughing the tertiary butyl under the effect of trifluoroacetic acid; Next, compound g obtains amide compound h with the reaction of different amine; At last, compound h just makes the compound shown in the general formula (I) with the indolone condensation of different replacements.
Wherein, in general formula (I) molecule two keys be configured as Z configuration (cis), this point can be inferred by nuclear magnetic data.Usually the chemical shift at NH on the pyrrole ring is about 9ppm, and in the compound that obtains the NH on the pyrrole ring about 14ppm, major cause is that the oxygen of NH and the indolone carbonyl that closes on the pyrrole ring has the intramolecular hydrogen bond effect, causes the chemical shift of NH to shift to low.This point also is described in patent WO0160814 (Su-11248).
Be used to further describe the present invention below in conjunction with embodiment, but these embodiment are not limiting scope of the present invention.
Embodiment
The structure of all derivative compounds that the present invention relates to is determined by nucleus magnetic resonance (NMR) or mass spectrum (MS).NMR displacement (δ) provides with 1,000,000/(ppm) unit.The mensuration of NMR is to use the BrukerAVANCE-400 nuclear magnetic resonance spectrometer, and measuring solvent is deuterochloroform (CDCl
3), deuterated dimethyl sulfoxide (DMSO-D
6), in be designated as tetramethylsilane (TMS), chemical shift is with 10
-6(ppm) provide as unit.
The mensuration of MS FINNIGAN LCQAd (ESI) mass spectrograph.
The mensuration of the average inhibiting rate of kinases VEGFR is used HTScan microplate reader (Cell Signaling company).
The mensuration of the average inhibiting rate of kinases EGFR/HER-2 is with NovoStar microplate reader (German BMG company).
Thin layer silica gel uses Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica-gel plate.
Column chromatography generally uses Huanghai Sea silica gel 200～300 order silica gel in Yantai to be carrier.
DMSO-D
6: deuterated dimethyl sulfoxide;
CDCl
3: deuterochloroform;
PCC: pyridine chromium trioxide hydrochloride
Preparation embodiment:
Embodiment 1
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
The first step
4,4,4-three fluoro-2-oximido 3-carbonyl-ethyl butyrates
Under the condition of ice bath, with 4,4,4-three fluoro-3-carbonyl-ethyl butyrate 1a (3.822 g, 20.75mmol) and Glacial acetic acid (6ml) join in the round-bottomed flask of 100ml, stir the aqueous solution (14.2g that dropwise drips Sodium Nitrite down, 20.75mmol be dissolved in the 4ml water), control reaction temperature is 0～5 ℃ in whole process, after dropping finishes, add water (1ml) again, in ice-water bath, react half an hour, remove ice-water bath, at room temperature continue about 3 hours of reaction, the point plate tracks to raw material and disappears, reaction finishes, and obtains title product 4,4, the solution of 4-three fluoro-2-oximido 3-carbonyl-ethyl butyrate 1b is directly cast single step reaction.
Second step
5-methyl-3-Trifluoromethyl-1 hydrogen-pyrroles-2, the 4 dicarboxylic acid-4-tert-butyl ester-2-ethyl ester
Get one and be furnished with thermometer, the three-necked flask of the 100ml of dropping funnel takes by weighing the 3-carbonyl-butyric acid-tert-butyl ester (3.28g, 20.75mmol), Glacial acetic acid (9.3ml) is warming up to 65 ℃ under stirring in three-necked bottle, weighing zinc powder (2.7g, 41.5mmol), drip the reaction solution 1b that the first step is reacted with dropping funnel, add zinc powder several times, water-bath hierarchy of control temperature remains on about 75 ℃, reacted 2 hours, and reduced the temperature to 40～45 ℃ then, reaction is spent the night.The point plate is followed the tracks of reaction and is finished, and adds entry (30ml) and ethyl acetate (50ml) in reaction solution, stirs after 15 minutes, with ethyl acetate (50ml * 3) extractive reaction liquid.Merge organic phase, water (50ml * 2), saturated sodium bicarbonate aqueous solution (50ml * 2), saturated sodium-chloride water solution (50ml * 2) washing successively, the ethyl acetate layer anhydrous sodium sulfate drying, filter, concentrating under reduced pressure, resistates obtains title product 5-methyl-3-Trifluoromethyl-1 hydrogen-pyrroles-2,4 dicarboxylic acid-4-tert-butyl ester-2-ethyl ester 1c (3.66g with toluene-normal hexane recrystallization, the cotton-shaped solid of white), productive rate: 55%.
MS?m/z(ESI)：320(M-1)。
1H?NMR(400MHz，CDCl
3-d)9.94(brs，1H，N
H)，4.37(q，J＝7.2Hz，2H，C
H 2CH
3)，2.45(s，3H，C
H 3)，1.56(s，9H，3×CC
H 3)，1.37(t，J＝7.2Hz，3H，CH
2C
H 3)。
The 3rd step
5-methyl-3-Trifluoromethyl-1 hydrogen-pyrroles-2, the 4 dicarboxylic acid-4-tert-butyl ester
In the round-bottomed flask of 1000ml, add 5-methyl-3-Trifluoromethyl-1 hydrogen-pyrroles-2 respectively, 4 dicarboxylic acid-4-the tert-butyl ester-2-ethyl ester 1c (19.0g, 59.2mmol), tetrahydrofuran (THF) (150ml), methyl alcohol (150ml), water (200ml) and potassium hydroxide (4.04g, 59.2mmol), be heated to 30 ℃, stirring is spent the night, next day, reaction solution is boiled off partial solvent to white solid occurring, add ethyl acetate (500ml) and saturated sodium bicarbonate solution (150ml) extractive reaction liquid, organic phase is used saturated sodium bicarbonate solution (150ml * 2) washing again, combining water layer, and it is 1 that water is regulated pH with concentrated hydrochloric acid, with ethyl acetate (200ml * 2) aqueous layer extracted, merge organic phase, the ethyl acetate layer anhydrous magnesium sulfate drying filters, filtrate decompression concentrate title product 5-methyl-3-Trifluoromethyl-1 hydrogen-pyrroles-2,4 dicarboxylic acid-4-tert-butyl ester 1d (9.8g, white solid), productive rate 56%.
The 4th step
5-methylol-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-4-tert-butyl ester
Under the nitrogen atmosphere, in the 250ml round-bottomed flask, with 5-methyl-3-Trifluoromethyl-1 hydrogen-pyrroles-2,4 dicarboxylic acid-4-tert-butyl ester 1d (9.8g, 33.4mmol) stir down and be dissolved in the anhydrous tetrahydro furan (20ml) tetrahydrofuran solution (67ml, the 1mol/L of dropping borine in reaction solution, 67mmol), stirring at room is 4 hours.The point plate tracks to raw material and disappears, and (2ml 50%v/v) with the cancellation reaction, adds ethyl acetate (200ml), again with saturated sodium bicarbonate solution abstraction reaction liquid (100ml * 3) slowly to drip dilute acetic acid in reaction solution.Merge organic phase, the ethyl acetate layer anhydrous magnesium sulfate drying, filter, filtrate decompression concentrates, with silica gel column chromatography purifying gained resistates (ethyl acetate/normal hexane=1: 4), obtain title product 5-methylol-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-4-tert-butyl ester 1e (5.0g, white solid), productive rate 55%.
MS?m/z(ESI)：278(M-1)。
1H?NMR(400MHz，CDCl
3-d)8.05(brs，1H，N
H)，4.80(s，2H，C
H 2OH)，2.47(s，3H，C
H 3)，1.55(s，9H，3×CC
H 3)。
The 5th step
5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-4-tert-butyl ester
With pyridine chromium trioxide hydrochloride (4.3g, 19.99mmol), sodium-acetate (1.0g, 12.36mmol) and methylene dichloride (50ml) add in the 250ml round-bottomed flask, stir the methylene dichloride suspension solution (5.0g of slow Dropwise 5-methylol-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-4-tert-butyl ester 1e down, 80ml), room temperature reaction 5 hours, some plate are followed the tracks of raw material and are disappeared substantially.Reaction solution is through diatomite filtration; concentrating under reduced pressure with silica gel column chromatography purifying gained resistates (ethyl acetate/normal hexane=1: 8), obtains title product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-4-tert-butyl ester 1f (3.51g; white solid), productive rate 70%.
MS?m/z(ESI)：276(M-1)。
1H?NMR(400MHz，CDCl
3-d)9.83(s，1H，C
HO)，9.57(brs，1H，N
H)，2.57(s，3H，C
H 3)，1.57(s，9H，3×CC
H 3)。
The 6th step
5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid
In the there-necked flask of 100ml; with 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-4-tert-butyl ester 1f (3.5g; 12.67mmol) be dissolved in the methylene dichloride (35ml), adding trifluoracetic acid under stirring (9.4ml, 126.7mmol); room temperature reaction 5 hours; the point plate is followed the tracks of raw material and is disappeared substantially, and the reaction solution concentrating under reduced pressure is spin-dried for solvent, obtains title product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid 1g (2.95g; white solid), productive rate 100%.Be directly used in next step reaction.
MS?m/z(ESI)：220(M-1)。
The 7th step
5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Under the nitrogen atmosphere; in the there-necked flask of a 250ml; with 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid 1g (2.95g; 12.67mmol) be dissolved in the N ' dinethylformamide (40ml); stir and add N-ethyl-N '-(dimethylamino-propyl)-carbodiimide hydrochloride (3.64g down successively; 19.00mmol); I-hydroxybenzotriazole (2.57g; 19.00mmol); triethylamine (3.2g; 31.68mmol) and diethylin ethamine (2.20g; 19.00mmol); stirring at room 8 hours; the point plate tracks to raw material and disappears substantially; add methylene dichloride (200ml) in the stirring downhill reaction liquid, with saturated sodium bicarbonate solution (80ml * 3) cleaning mixture, combining water layer methylene dichloride (80ml * 1) Hui Cui.Merge organic phase; the dichloromethane layer anhydrous sodium sulfate drying filters, and filtrate decompression concentrates title product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-acid amides 1h (5.1g; oily matter), directly carry out next step reaction.
MS?m/z(ESI)：320(M+1)。
The 8th step
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Directly be not dissolved in the ethanol (10ml) previous step product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1h (5.1g) is purified; stir and add 5-fluoro-1 down; 3-dihydro-indol-2-one (1.53g; 10.14mmol) and hexahydropyridine (85mg; 1.01mmol); reflux 8 hours; the point plate tracks to raw material and disappears substantially; reaction solution naturally cools to room temperature; there is yellow solid to produce; filter, solid washs with cold ethanol (2ml * 2), vacuum-drying; obtain title product 5-(5-fluoro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-and 2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1 (3.4g, yellow solid), productive rate 55%.
MS?m/z(ESI)：453(M+1)。
1H?NMR(400MHz，DMSO-d6)7.61(d，J＝8.4Hz，1H，Ar
H)，7.57(s，1H，C
H)，7.07(m，1H，Ar
H)，，6.92(m，1H，Ar
H)，3.28(t，J＝6.8Hz，2H，NCH
2CH
2NEt
2)，2.51(m，6H，2×NC
H 2CH
3?and?C
H 2NEt
2)，2.39(s，3H，C
H 3)，0.97(t，J＝6.8Hz，6H，2×NCH
2C
H 3)。
Embodiment 2
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Repeat the embodiment of the invention reaction in seven steps of 1 the first step to the; different be to use that resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1h makes raw material in above-mentioned the 7th step; make this raw material and 5-chloro-1 according to described same way as of the embodiment of the invention 1 the 8th step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-chloro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 2 (98mg; yellow solid), productive rate: 35.4%.
MS?m/z(ESI)：469(M+1)。
1H?NMR(400MHz，DMSO-d6)7.83(s，1H，Ar
H)，7.62(s，1H，C
H)，7.27(d，J＝8.4Hz，1H，Ar
H)，6.94(d，J＝8.4Hz，1H，Ar
H)，3.28(t，J＝6.8Hz，2H，NC
H 2CH
2NEt
2)，2.51(m，6H，2×NC
H 2CH
3?and?C
H 2NEt
2)，2.39(s，3H，C
H 3)，0.97(t，J＝6.8Hz，6H，2×NCH
2C
H 3)。
Embodiment 3
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Repeat the embodiment of the invention reaction in seven steps of 1 the first step to the; different be to use that resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1h makes raw material in above-mentioned the 7th step; make this raw material and 5-chloro-1 according to described same way as of the embodiment of the invention 1 the 8th step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-bromo-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 3 (124mg; yellow solid), productive rate: 38%.
MS?m/z(ESI)：513(M)。
1H?NMR(400MHz，DMSO-d6)7.94(s，1H，Ar
H)，7.61(s，1H，C
H)，7.39(d，J＝8.4Hz，1H，Ar
H)，6.89(d，J＝8.0Hz，1H，Ar
H)，3.28(t，J＝6.8Hz，2H，NC
H 2CH
2NEt
2)，2.51(m，6H，2×NC
H 2CH
3?and?C
H 2NEt
2)，2.39(s，3H，C
H 3)，0.97(t，J＝6.8Hz，6H，2×NCH
2C
H 3)。
Embodiment 4
5-(5-Toluidrin-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Repeat the embodiment of the invention reaction in seven steps of 1 the first step to the; resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1h makes raw material in above-mentioned the 7th step of different uses; make this raw material and 5-Toluidrin-1 according to described same way as of the embodiment of the invention 1 the 8th step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-Toluidrin-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 4 (50mg; yellow solid), productive rate: 15%.
MS?m/z(ESI)：528(M+1)。
1H?NMR(400MHz，DMSO-d6).14.14(s，1H，N
H)，12.23(s，1H，N
H)，9.40(s，1H，N
H)，8.03(s，1H，N
H)，7.46(s，1H，Ar
H)，7.44(d，J＝8.4Hz，1H，Ar
H)，7.16(d，J＝8.4Hz，1H，Ar
H)，6.93(d，J＝8.0Hz，1H，Ar
H)，3.28(t，J＝6.8Hz，2H，NC
H 2CH
2NEt
2)，2.95(s，3H，C
H 3SO
2)，2.51(m，6H，2×NC
H 2CH
3?and?C
H 2NEt
2)，2.40(s，3H，C
H 3)，0.97(t，J＝6.8Hz，6H，2×NCH
2C
H 3)。
Embodiment 5
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Repeat the embodiment of the invention reaction in seven steps of 1 the first step to the; different be to use that resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1h makes raw material in above-mentioned the 7th step; make this raw material and 5-ethanamide-1 according to described same way as of the embodiment of the invention 1 the 8th step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-ethanamide-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 5 (120mg; yellow solid), productive rate: 38.7%.
MS?m/z(ESI)：492(M+1)。
1H?NMR(400?MHz，DMSO-d6)7.79(s，1H，Ar
H)，7.44(d，J＝8.4Hz，1H，Ar
H)，7.39(s，1H，C
H)，6.88(d，J＝8.0Hz，1H，Ar
H)，3.28(t，J＝6.8Hz，2H，NC
H 2CH
2NEt
2)，2.51(m，6H，2×NC
H 2CH
3?and?C
H 2NEt
2)，2.38(s，3H，C
H 3)，2.04(s，3H，C
H 3CO)，0.97(t，J＝6.8Hz，6H，2×NCH
2C
H 3)。
Embodiment 6
5-(6-ethanamide-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide
Compound 6-ethanamide-5-fluoro-1, the 3-dihydro-indol-2-one is by 6-amino-5-fluoro-1, and the excess acetyl chloride of 3-dihydro-indol-2-one and equivalent is prepared from.
Repeat the embodiment of the invention reaction in seven steps of 1 the first step to the; different be to use that resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 1h makes raw material in above-mentioned the 7th step; make this raw material and 6-ethanamide-5-fluoro-1 according to described same way as of the embodiment of the invention 1 the 8th step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(6-ethanamide-5-fluoro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide 6 (84mg; yellow solid), productive rate: 26%.
MS?m/z(ESI)：510(M+1)。
1H?NMR(400MHz，DMSO-d6)7.71(s，1H，Ar
H)，7.68(s，1H，Ar
H)，7.46(s，1H，C
H)，3.27(t，J＝6.8Hz，2H，NC
H 2CH
2NEt
2)，2.51(m，6H，2×NC
H 2CH
3?andC
H 2NEt
2)，2.37(s，3H，C
H 3)，2.12(s，3H，C
H 3CO)，0.97(t，J＝6.8Hz，6H，2×NCH
2C
H 3)。
Embodiment 7
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
The first step
5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
According to described same way as of the 7th step of the embodiment of the invention 1; under the nitrogen atmosphere; in the there-necked flask of a 250ml; with 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid 1g (0.605g; 2.73mmol) be dissolved in the N ' dinethylformamide (8.5ml); stir and add N-ethyl-N '-(dimethylamino-propyl)-carbodiimide hydrochloride (1.047g down successively; 5.46mmol); I-hydroxybenzotriazole (553mg; 2.73mmol); triethylamine (0.689g; 6.83mmol) and N-morphine quinoline-4-base-ethamine (532mg; 4.095mmol); stirring at room 8 hours, the some plate tracks to raw material and disappears substantially, stirs in the downhill reaction liquid to add methylene dichloride (200ml); with saturated sodium bicarbonate solution (80ml * 2) cleaning mixture, combining water layer methylene dichloride (50ml * 1) Hui Cui.Merge organic phase; the dichloromethane layer anhydrous sodium sulfate drying filters, and filtrate decompression concentrates title product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 7a (1.190g; oily matter), directly carry out next step reaction.
Second step
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
According to described same way as of the 8th step of the embodiment of the invention 1; with previous step product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 7a (137mg; 0.41mmol) not purified directly being dissolved in the ethanol (2ml); stir and add 5-fluoro-1 down; 3-dihydro-indol-2-one (59mg; 0.39mmol) and hexahydropyridine (4mg; 0.04mmol); reflux 8 hours, the some plate tracks to raw material and disappears substantially, and reaction naturally cools to room temperature; there is yellow solid to produce; filter, solid washs with cold ethanol (5ml), vacuum-drying; obtain title product 5-(5-fluoro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-and 2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 7 (84mg, yellow solid), productive rate 44%.
MS?m/z(ESI)：467(M+1)。
1H?NMR(400?MHz，DMSO-d6)7.63(d，J＝8.4Hz，1H，Ar
H)，7.58(s，1H，C
H)，7.07(d，J＝8.0Hz，1H，Ar
H)，6.93(m，1H，Ar
H)，3.57(t，J＝6.8Hz，4H，2×NCH
2C
H 2O)，3.35(t，J＝6.8Hz，2H，NC
H 2CH
2N)，2.45(m，6H，2×NC
H 2CH
2O?andNCH
2C
H 2N)，2.34(s，3H，C
H 3)。
Embodiment 8
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 7 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-morphine quinoline-4-base-ethyl)-methane amide 7a that are to use make raw material; make this raw material and 5-chloro-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-chloro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 8 (98mg; orange/yellow solid), productive rate: 35.6%.
MS?m/z(ESI)：483(M+1)。
1H?NMR(400MHz，DMSO-d6)7.83(s，1H，Ar
H)，7.62(s，1H，C
H)，7.28(d，J＝8.0Hz，1H，Ar
H)，6.95(d，J＝8.0Hz，1H，Ar
H)，3.57(m，4H，2×NCH
2C
H 2O)，3.38(t，J＝6.8Hz，2H，NC
H 2CH
2N)，2.45(m，6H，2×NC
H 2CH
2O?and?NCH
2C
H 2N)，2.34(s，3H，C
H 3)。
Embodiment 9
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 7 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-morphine quinoline-4-base-ethyl)-methane amide 7a that are to use make raw material; make this raw material and 5-bromo-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-bromo-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 9 (77mg; yellow solid)
Productive rate: 37%.
MS?m/z(ESI)：527(M)。
1H?NMR(400MHz，DMSO-d6)7.98(s，1H，Ar
H)，7.63(s，1H，C
H)，7.40(d，J＝8.4Hz，1H，Ar
H)，6.90(d，J＝8.0Hz，1H，Ar
H)，3.57(t，J＝6.8Hz，4H，2×NCH
2C
H 2O)，3.34(t，J＝6.8Hz，2H，NC
H 2CH
2N)，2.43(m，6H，2×NC
H 2CH
2O?andNCH
2C
H 2N)，2.39(s，3H，C
H 3)。
Embodiment 10
5-(5-Toluidrin-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 7 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-morphine quinoline-4-base-ethyl)-methane amide 7a that are to use make raw material; make this raw material and 5-Toluidrin-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-Toluidrin-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 10 (35mg; yellow solid), productive rate: 16%.
MS?m/z(ESI)：542(M+1)。
1H?NMR(400MHz，DMSO-d6)7.46(s，1H，Ar
H)，7.43(s，1H，C
H)，7.15(d，J＝8.4Hz，1H，Ar
H)，6.94(d，J＝8.0Hz，1H，Ar
H)，3.66(t，J＝6.8Hz，4H，2×NCH
2C
H 2O)，3.30(t，J＝6.8Hz，2H，NC
H 2CH
2N)，2.98(s，3H，C
H 3SO
2)，2.43(m，6H，2×NC
H 2CH
2O?and?NCH
2C
H 2N)，2.39(s，3H，C
H 3)。
Embodiment 11
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 7 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-morphine quinoline-4-base-ethyl)-methane amide 7a that are to use make raw material; carry out this raw material and 5-ethanamide-1 according to described same way as of 7 second step of the embodiment of the invention; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-ethanamide-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 11 (86mg; yellow solid), productive rate: 31.5%.
MS?m/z(ESI)：506(M)。
1H?NMR(400MHz，DMSO-d6)7.79(s，1H，Ar
H)，7.44(d，J＝8.4Hz，1H，Ar
H)，7.40(s，1H，C
H)，6.88(d，J＝8.0Hz，1H，Ar
H)，3.57(m，4H，2×NCH
2C
H 2O)，3.34(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.44(m，6H，2×NC
H 2CH
2O?and?NCH
2C
H 2N)，2.40(s，3H，C
H 3)，2.04(s，3H，C
H 3CO)。
Embodiment 12
5-(6-amino-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 7 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-morphine quinoline-4-base-ethyl)-methane amide 7a that are to use make raw material; make this raw material and 6-amino-5-fluoro-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(6-amino-5-fluoro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide 12 (115mg; yellow solid), productive rate: 61%.
MS?m/z(ESI)：482(M+1)。
1H?NMR(400MHz，DMSO-d6)7.36(d，J＝10.8Hz，1H，Ar
H)，7.16(s，1H，C
H)，6.37(d，J＝7.6Hz，1H，Ar
H)，3.58(m，4H，2×NCH
2C
H 2O)，3.32(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.42(m，6H，2×NC
H 2CH
2O?and?NCH
2C
H 2N)，2.34(s，3H，C
H 3)。
Embodiment 13
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
The first step
5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
According to described same way as of the 7th step of the embodiment of the invention 1; under the nitrogen atmosphere; in the there-necked flask of a 250ml; with 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid 1g (0.605g; 2.73mmol) be dissolved in the N ' dinethylformamide (8ml); stir and add N-ethyl-N '-(dimethylamino-propyl)-carbodiimide hydrochloride (1.047g down successively; 5.46mmol); I-hydroxybenzotriazole (0.553g; 4.09mmol); triethylamine (0.689g; 6.82mmol) and N-piperidines-1-base-ethamine (0.525g; 4.09mmol); stirring at room 8 hours, the some plate tracks to raw material and disappears substantially, stirs in the downhill reaction liquid to add methylene dichloride (200ml); with saturated sodium bicarbonate solution (80ml * 2) cleaning mixture, combining water layer methylene dichloride (50ml * 1) Hui Cui.Merge organic phase; the dichloromethane layer anhydrous sodium sulfate drying filters, and filtrate decompression concentrates title product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 13a (1.188g; oily matter), directly carry out next step reaction.
Second step
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
According to described same way as of the 8th step of the embodiment of the invention 1; with previous step product 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 13a (121mg; 0.364mmol) not purified being dissolved in the ethanol (2ml); stir and add 5-fluoro-1 down; 3-dihydro-indol-2-one (52mg; 0.346mmol) and hexahydropyridine (3mg; 0.036mmol); reflux 8 hours, the some plate tracks to raw material and disappears substantially, and reaction naturally cools to room temperature; there is yellow solid to produce; filter, solid washs with cold ethanol (5ml), vacuum-drying; obtain title product 5-(5-fluoro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-and 2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 7 (62mg, yellow solid), productive rate 37%.
MS?m/z(ESI)：465(M+1)。
1H?NMR(400MHz，DMSO-d6)7.63(d，J＝6.8Hz，1H，Ar
H)，7.58(s，1H，C
H)，7.06(m，1H，Ar
H)，6.93(m，1H，Ar
H)，3.32(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.45(s，3H，C
H 3)，2.39(m，6H，2×CH
2NC
H 2CH
2?and?NCH
2C
H 2N)，1.50(m，4H，C
H 2CH
2C
H 2)，1.38(m，2H，CH
2C
H 2CH
2)。
Embodiment 14
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 13 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-piperidines-1-base-ethyl)-methane amide 13a that are to use make raw material; make this raw material and 5-chloro-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-chloro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 14 (84mg; yellow solid), productive rate: 50%.
MS?m/z(ESI)：481(M+1)。
1H?NMR(400MHz，DMSO-d6)7.83(s，1H，Ar
H)，7.62(s，1H，C
H)，7.27(d，J＝8.4Hz，1H，Ar
H)，6.95(d，J＝8.4Hz，1H，Ar
H)，3.32(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.41(s，3H，C
H 3)，2.38(m，6H，2×CH
2NC
H 2CH
2?and?NCH
2C
H 2N)，1.50(m，4H，C
H 2CH
2C
H 2)，1.38(m，2H，CH
2C
H 2CH
2)。
Embodiment 15
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 13 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-piperidines-1-base-ethyl)-methane amide 13a that are to use make raw material; make this raw material and 5-bromo-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-bromo-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 15 (110mg; yellow solid), productive rate: 21%.
MS?m/z(ESI)：525(M)。
1H?NMR(400MHz，DMSO-d6)7.96(s，1H，Ar
H)，7.62(s，1H，C
H)，7.40(d，J＝8.4Hz，1H，Ar
H)，6.90(d，J＝8.4Hz，1H，Ar
H)，3.32(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.41(s，3H，C
H 3)，2.37(m，6H，2×CH
2NC
H 2CH
2?and?NCH
2C
H 2N)，1.50(m，4H，C
H 2CH
2C
H 2)，1.38(m，2H，CH
2C
H 2CH
2)。
Embodiment 16
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 13 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-piperidines-1-base-ethyl)-methane amide 13a that are to use make raw material; make this raw material and 5-ethanamide-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(5-ethanamide-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 16 (76mg; yellow solid), productive rate: 44%.
MS?m/z(ESI)：504(M+1)。
1H?NMR(400MHz，DMSO-d6)7.79(s，1H，Ar
H)，7.44(d，J＝8.4Hz，1H，Ar
H)，7.39(s，1H，C
H)，6.88(d，J＝8.4Hz，1H，Ar
H)，3.30(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.41(s，3H，C
H 3)，2.38(m，6H，2×CH
2NC
H 2CH
2?and?NCH
2C
H 2N)，2.03(s，3H，C
H 3CO)，1.50(m，4H，C
H 2CH
2C
H 2)，1.38(m，2H，CH
2C
H 2CH
2)。
Embodiment 17
5-(6-amino-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide
Repeat the reaction of the embodiment of the invention 13 the first steps; different resulting compound 5-formyl radical-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid in the above-mentioned the first step-(2-piperidines-1-base-ethyl)-methane amide 13a that are to use make raw material; make this raw material and 6-amino-5-fluoro-1 according to described same way as of the embodiment of the invention 7 second step; the reaction of 3-dihydro-indol-2-one; then obtain title product 5-(6-amino-5-fluoro-2-oxo-1; 2-dihydro-indoles-3-subunit-methyl)-and 2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide 17 (130mg), productive rate: 78%.
MS?m/z(ESI)：480(M+1)。
1H?NMR(400MHz，DMSO-d6)7.35(d，J＝7.6Hz，1H，Ar
H)，7.16(s，1H，C
H)，6.37(d，J＝7.6Hz，1H，Ar
H)，3.32(t，J＝6.4Hz，2H，NC
H 2CH
2N)，2.39(m，6H，2×CH
2NC
H 2CH
2?and?NCH
2C
H 2N)，2.30(s，3H，C
H 3)，1.49(m，4H，C
H 2CH
2C
H 2)，1.37(m，2H，CH
2C
H 2CH
2)。
Test case:
The mensuration of kinase inhibiting activity
At target spot VEGFR, detection mode is that (Time-resolvedFluorescence TRF), uses the HTScan VEGF-R2 Kinase Assay Kit (Cat.No.7788) of Cell Signaling company to time-resolved fluoroimmunoassay, tests highly sensitive.Through groping of experiment condition repeatedly, determine that in 30 μ l reaction systems use reorganization VEGFR2 albumen 6U, concentration of substrate is 1.5 μ M, suppressing compound concentration is the basic parameters of 10 μ M as screening model, and testing compound is screened;
At target spot EGFR/HER-2, use the K-LISA of CALBIOCHEM company
TM96 hole elisa plates of PTK ScreeningKit (Cat.No.539701) and EGFR/HER-2 effect E4Y substrate bag quilt, kinases (rat spleen extract) 0.25-1 μ g is used in the reaction of every hole, using the inhibition compound concentration simultaneously is the basic parameter of the experiment condition of 50 μ M as the screening platform, so that testing compound is screened.
The present invention records the EGFR/HER-2 of compound and the average kinase inhibition rate of VEGFR sees Table 1
The average kinase inhibition rate of table 1 EGFR/HER-2 and VEGFR
Claims (6)
1. 2-indolinone derivative or its salt that replaces by the pyrroles of general formula (I) expression:
Wherein:
R
1, R
2, R
3And R
4Be selected from respectively hydrogen atom, halogen, alkyl, haloalkyl, halogenated alkoxy, cycloalkyl, thiazolinyl, alkynyl, aryl, heteroaryl, Heterocyclylalkyl, hydroxyl ,-OR
8,-O[CH
2CH
2O]
rR
11,-SR
8,-NR
10R
11,-SOR
8,-SO
2R
8,-NSO
2R
8,-SO
2NR
8R
9,-(CH
2)
nCOOR
8,-(CH
2)
nCONR
8R
9,-C (=S) NR
8R
9,-COR
8,-NR
8COR
9,-NHC (=O) OR
9,-OCOOR
9,-OCONR
8R
9,-CN or-NO
2, wherein aryl, heteroaryl, Heterocyclylalkyl functional group can further be replaced by alkyl or halogen;
R
5And R
6Have at least one to be trifluoromethyl; R
5And R
6Be selected from hydrogen atom, alkyl, aryl or trifluoromethyl respectively;
R
7Be selected from hydrogen atom, alkyl or-(CO) R
10
R
8And R
9Be selected from hydrogen atom, alkyl, cycloalkyl, aryl, heteroaryl or Heterocyclylalkyl respectively, wherein alkyl, cycloalkyl, aryl, heteroaryl or Heterocyclylalkyl can further be replaced by one or more alkyl, aryl, hydroxyl, amino, alkylamino, amide group, amine acyl group, cyano group, alkoxyl group, aryloxy, amine alkyl, hydroxyalkyl, Heterocyclylalkyl, carboxylic acid or carboxylicesters;
Simultaneously, R
8And R
9Can form 4～8 yuan of heterocyclic radicals; Wherein can further contain one or more N, O, S atom in 5～8 yuan of heterocycles, and can be further on 4～8 yuan of heterocycles by one or more alkyl, aryl, heteroaryl, haloalkyl, halogenated alkoxy, hydroxyl, amino, alkylamino, amide group, amine acyl group, cyano group, alkoxyl group, aryloxy, amine alkyl, hydroxyalkyl, Heterocyclylalkyl, carboxylic acid, carboxylicesters, halogen or-NR
8R
9Replace;
R
10Be selected from hydroxyl, alkoxyl group, aryloxy, heterocycle alkoxyl group, aralkoxy ,-N (R
11) (CH
2)
mR
12,-NR
11[CH
2CH
2O]
rR
11,-NR
8R
9Perhaps-NR
11(CH
2)
m[CH (OH) CH
2]
pZ, wherein Z be aryl, heteroaryl, Heterocyclylalkyl ,-NR
8R
9,-COOR
11Or CONR
8R
9
R
11Be selected from hydrogen atom or alkyl;
R
12Be selected from-NR
8R
9, hydroxyl, aryl, heteroaryl, alkoxyl group ,-O[CH
2CH
2O]
rR
11,-N
+(O
-) R
8R
9,-N (OH) R
8,-NHC (O) R
13Or-COR
13, R wherein
13Be unsubstituted alkyl, haloalkyl or aralkyl;
N is 0～4;
R is 1～6;
M is 1～6;
P is 1～2.
2. 2-indolinone derivative or its salt, wherein R that pyrroles according to claim 1 replaces
5It is trifluoromethyl;
3. compound or its salt according to claim 1 and 2, comprising:
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-Toluidrin-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(6-ethanamide-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-diethylin-ethyl)-methane amide;
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-Toluidrin-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(6-amino-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-morphine quinoline-4-base-ethyl)-methane amide;
5-(5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide;
5-(5-chloro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide;
5-(5-bromo-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide;
5-(5-ethanamide-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide; With
5-(6-amino-5-fluoro-2-oxo-1,2-dihydro-indoles-3-subunit-methyl)-2-methyl-4-Trifluoromethyl-1 hydrogen-pyrroles-3-carboxylic acid-(2-piperidines-1-base-ethyl)-methane amide.
4. the preparation method of the 2-indolinone derivative that pyrroles according to claim 1 and 2 replaces may further comprise the steps:
Trifluoromethyl compound a is pressed the following formula cyclization generate trifluoromethyl compound c;
Described trifluoromethyl compound c is become compound d by the mineral alkali selective hydrolysis;
Trifluoromethyl compound e is oxidized to compound f by PCC.
5. pharmaceutical composition, it comprises any one described pyrroles replaces in the claim 1～3 of medicine effective dose 2-indolinone derivative or its salt and pharmaceutically acceptable carrier.
6. according to the purposes of any one described compound or its salt in the claim 1～3 in the preparation kinases inhibitor.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100650024A CN101007801A (en) | 2006-01-27 | 2006-03-15 | Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses |
| PCT/CN2007/000323 WO2007085205A1 (en) | 2006-01-27 | 2007-01-29 | Pyrrole substituted 2-indolinone derivatives, the preparation methods and medical uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610003228 | 2006-01-27 | ||
| CN200610003228.1 | 2006-01-27 | ||
| CNA2006100650024A CN101007801A (en) | 2006-01-27 | 2006-03-15 | Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101007801A true CN101007801A (en) | 2007-08-01 |
Family
ID=38308869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100650024A Pending CN101007801A (en) | 2006-01-27 | 2006-03-15 | Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101007801A (en) |
| WO (1) | WO2007085205A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009140928A1 (en) * | 2008-05-23 | 2009-11-26 | 上海医药工业研究院 | Dihydroindolinone derivatives |
| CN102532118A (en) * | 2010-12-24 | 2012-07-04 | 沈阳药科大学 | Indolone-containing 4-thiazolidone derivatives and application thereof |
| CN101440086B (en) * | 2007-11-20 | 2013-04-10 | 上海医药工业研究院 | Halogenated pyrrole substituted indolinones, and intermediate, preparation and use thereof |
| CN108727341A (en) * | 2017-04-13 | 2018-11-02 | 上海先行医药开发有限公司 | A kind of pyrroles's substituted indole ketones derivant or its pharmaceutically acceptable salt and their preparation method and purposes |
| CN110818703A (en) * | 2019-11-22 | 2020-02-21 | 河南理工大学 | Pyrrole-part cyanine derivative fluorescent probe and preparation method and application thereof |
| US12018014B2 (en) | 2018-09-19 | 2024-06-25 | Suzhou Genhouse Pharmaceutical Co., Ltd. | Pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and preparation method therefor and application thereof |
| WO2025007853A1 (en) * | 2023-07-05 | 2025-01-09 | 远森制药（杭州）有限公司 | 2-indolinone compound serving as vegfr and pka dual-target inhibitor, and preparation method therefor and use thereof |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006029795A1 (en) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | New urea derivatives and their uses |
| WO2008033562A2 (en) | 2006-09-15 | 2008-03-20 | Xcovery, Inc. | Kinase inhibitor compounds |
| CN101412711A (en) * | 2007-10-15 | 2009-04-22 | 上海恒瑞医药有限公司 | Carbamate derivatives and use thereof in medicine |
| CN102276584A (en) * | 2010-06-08 | 2011-12-14 | 齐鲁制药有限公司 | Pyrrole-substituted 2-dihydroindolone derivative and preparation method and application thereof |
| WO2014160401A1 (en) * | 2013-03-13 | 2014-10-02 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| CN104829596B (en) | 2014-02-10 | 2017-02-01 | 石家庄以岭药业股份有限公司 | Pyrrole-substituted indolinone derivative and preparation method thereof, composition including derivative, and application of derivative |
| CN105566302B (en) * | 2014-10-08 | 2018-08-14 | 齐鲁制药有限公司 | The crystallization of indolinone compounds and its salt |
| CN104876928B (en) * | 2015-05-07 | 2016-09-14 | 浙江司太立制药股份有限公司 | 7-azaidolin-2-one compound and its preparation method |
| CN106432228A (en) * | 2016-09-06 | 2017-02-22 | 浙江司太立制药股份有限公司 | 4-oximido-1-piperidyl fragment containing 7-azaindolin-2-one compound and preparation method therefor |
| CN106397436A (en) * | 2016-09-06 | 2017-02-15 | 浙江司太立制药股份有限公司 | 5-bromo-7-azaindoline-2-one compounds and preparation method thereof |
| TW202506661A (en) * | 2023-08-11 | 2025-02-16 | 大陸商勤浩醫藥(蘇州)有限公司 | Medicinal salt, crystal form and preparation method of tyrosine kinase inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1255752E (en) * | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| WO2002081466A1 (en) * | 2001-04-09 | 2002-10-17 | Sugen, Inc. | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| MXPA04003385A (en) * | 2001-10-10 | 2005-04-11 | Sugen Inc | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors. |
| CA2466807A1 (en) * | 2001-11-21 | 2003-06-05 | Sugen, Inc. | Pharmaceutical formulations comprising indolinone derivatives |
| HN2003000272A (en) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | FORMULATIONS THAT INCLUDE AN INDOLINONE COMPOUND |
-
2006
- 2006-03-15 CN CNA2006100650024A patent/CN101007801A/en active Pending
-
2007
- 2007-01-29 WO PCT/CN2007/000323 patent/WO2007085205A1/en not_active Ceased
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101440086B (en) * | 2007-11-20 | 2013-04-10 | 上海医药工业研究院 | Halogenated pyrrole substituted indolinones, and intermediate, preparation and use thereof |
| WO2009140928A1 (en) * | 2008-05-23 | 2009-11-26 | 上海医药工业研究院 | Dihydroindolinone derivatives |
| CN102066362B (en) * | 2008-05-23 | 2014-07-30 | 上海医药工业研究院 | Dihydroindolinone derivatives |
| US8829039B2 (en) | 2008-05-23 | 2014-09-09 | Shanghai Institute Of Pharmaceutical Industry | Dihydroindolinone derivatives |
| CN102532118A (en) * | 2010-12-24 | 2012-07-04 | 沈阳药科大学 | Indolone-containing 4-thiazolidone derivatives and application thereof |
| CN102532118B (en) * | 2010-12-24 | 2014-04-09 | 沈阳药科大学 | Indolone-containing 4-thiazolidone derivatives and application thereof |
| CN108727341A (en) * | 2017-04-13 | 2018-11-02 | 上海先行医药开发有限公司 | A kind of pyrroles's substituted indole ketones derivant or its pharmaceutically acceptable salt and their preparation method and purposes |
| CN108727341B (en) * | 2017-04-13 | 2021-02-19 | 勤浩医药（苏州）有限公司 | Pyrrole substituted indolone derivative or pharmaceutically acceptable salt thereof, and preparation method and application thereof |
| US12018014B2 (en) | 2018-09-19 | 2024-06-25 | Suzhou Genhouse Pharmaceutical Co., Ltd. | Pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and preparation method therefor and application thereof |
| CN110818703A (en) * | 2019-11-22 | 2020-02-21 | 河南理工大学 | Pyrrole-part cyanine derivative fluorescent probe and preparation method and application thereof |
| WO2025007853A1 (en) * | 2023-07-05 | 2025-01-09 | 远森制药（杭州）有限公司 | 2-indolinone compound serving as vegfr and pka dual-target inhibitor, and preparation method therefor and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007085205A1 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101007801A (en) | Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses | |
| EP3365335B1 (en) | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases | |
| ES2920702T3 (en) | Heteroaryl Compounds as Kinase Inhibitors | |
| ME00415B (en) | Pyrrole substituted 2-indolinone protein kinase inhibitors | |
| CA2495216A1 (en) | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | |
| JP2003534341A (en) | Prodrugs of 3- (pyrrole-2-ylmethylidene) -2-indolinone derivatives | |
| WO2008138184A1 (en) | Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases | |
| CN103097381A (en) | 1, 8-naphthyridines as kinase inhibitors | |
| CN101007814A (en) | Pyrrolehexa-heterocyclic compound and pharmaceutical use thereof | |
| CN118580225A (en) | A PRMT5-MTA synergistic inhibitor and its application | |
| CN109793733B (en) | 3-amino-5-alkynyl pyrazole compounds as FGFR inhibitors | |
| CN101367801B (en) | Preparation method for pyrrol-hexahydric N heterocycle hydroxyl morpholine derivants, and medical uses thereof | |
| Grosios et al. | Tyrosine kinase targets in drug discovery | |
| TW200835480A (en) | Azulene compounds | |
| CN101007815B (en) | Pyrrolehexa-heterocyclic compound and pharmaceutical use thereof | |
| TWI699366B (en) | Compounds for treating or preventing cancer | |
| CA3147649C (en) | Pyrazole derivatives and use thereof | |
| CN115260156A (en) | Compounds as JAK2 inhibitors and uses thereof | |
| HK1159108A1 (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof | |
| HK1159108B (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |